Skip to main content

Caliper Teams with Horizon on Oncology Cell Lines

NEW YORK (GenomeWeb News) – Caliper Life Sciences today announced that it is incorporating Horizon Discovery’s oncology cell lines into its offerings from Caliper Discovery Alliances and Services.
 
According to Hopkinton, Mass.-based Caliper, the deal provides CDAS with unique, genetically defined, and isogenic human cancer cell lines that will enable researchers to better identify and characterize personalized drugs targeted at specific subsets of patients.
 
The firm said that the cell lines provide scientists with a better understanding of the mechanism of action of compounds, directly identify patient-relevant compounds from large compound libraries, re-profile existing drugs for new indications, and identify potential side effects early in the drug development process.
 
Caliper expects the cell lines to “enhance the success rate and reduce the cost of discovering targeted monotherapy or combination therapies that better treat disease with fewer adverse events,” David Manyak, Caliper’s EVP of drug discovery services, said in a statement.
 
The firms did not disclose terms of the alliance.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.